Gene | Associated with NEVUS, EPIDERMAL in | Link to HGNC | Cytogenetic band | Number of associated diseases | Associated diseases |
---|---|---|---|---|---|
PIK3CA | ClinVar, OMIM | HGNC link | 3q26.32 | 11 | 114550, PS158350, 167000, 612918, 211980, 114480, 602501, 114500, 182000, 162900, 613659 |
HRAS | ClinVar, OMIM | HGNC link | 11p15.5 | 6 | 218040, 137550, 185500, 109800, 163200, 162900 |
NRAS | ClinVar, OMIM, HUMSAVAR | HGNC link | 1p13.2 | 8 | 137550, PS163950, 249400, 163200, 607785, 114500, 614470, 162900 |
FGFR3 | ClinVar, OMIM, HUMSAVAR | HGNC link | 4p16.3 | 16 | 603956, 109800, 149730, 101400, 100800, 610474, 182000, 162900, 612247, 146000, 602849, 114500, 273300, 187600, 187601, 616482 |
KRAS | ClinVar | HGNC link | 12p12.1 | 14 | 601626, 600268, 137215, 109800, PS163950, 211980, 114480, PS115150, 613659, 163200, 607785, 614470, 162900, 260350 |
Download the disease annotation in CSV format
regulated gene | associated to this disease | # TFs | TFs | # TFs associated with this disease | TFs associated with this disease |
---|---|---|---|---|---|
PIK3CA | YES | 1 | FOXO3 | 0 | |
HRAS | YES | 3 | SP1, MAZ, TP53 | 0 | |
NRAS | YES | 1 | AR | 0 | |
FGFR3 | YES | 5 | SP1, SP3, SP4, STAT1, SHOX | 0 | |
KRAS | YES | 1 | MYC | 0 |
Gene1 | Gene2 | Direct Interaction | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|
PIK3CA | HRAS | Yes | 5 | ARHGEF1, CBL, PIK3R1, IL24, DGKZ |
PIK3CA | NRAS | No | 1 | RPS20 |
PIK3CA | FGFR3 | No | 1 | GRB2 |
PIK3CA | KRAS | Yes | 4 | THRSP, TNFSF13, IL24, PIK3R2 |
HRAS | NRAS | No | 7 | RAP1GDS1, RABGGTB, MLLT4, RAF1, PIK3CG, RGL2, TMEM185A |
HRAS | KRAS | No | 10 | RALGDS, RASSF5, RGL2, IL24, PIK3CA, BTRC, RAF1, PIK3CG, RAP1GDS1, SHOC2 |
NRAS | KRAS | No | 6 | RGL2, RAP1GDS1, ELAVL1, PIK3CG, RAF1, EEF1A1 |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct Interaction | Complexes | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|---|
HRAS | NRAS | Yes | RAF1-RAS complex, EGF induced | 2 | KRAS, RAF1 |
HRAS | KRAS | Yes | RAF1-RAS complex, EGF induced | 2 | NRAS, RAF1 |
NRAS | KRAS | Yes | RAF1-RAS complex, EGF induced | 2 | HRAS, RAF1 |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct interaction | More information |
---|---|---|---|
HRAS | KRAS | No | |
HRAS | NRAS | maybe, indirect | They are member of the same protein family. |
KRAS | NRAS | maybe, indirect | They are members of the same protein family. |
KEGG term | KEGG term ID | IC | Number of genes with the same term | Genes |
---|---|---|---|---|
Signaling pathways regulating pluripotency of stem cells | hsa04550 | 5.6 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
MicroRNAs in cancer | hsa05206 | 5.38 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Pathways in cancer | hsa05200 | 3.98 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Rap1 signaling pathway | hsa04015 | 4.97 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Ras signaling pathway | hsa04014 | 4.9 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Central carbon metabolism in cancer | hsa05230 | 6.7 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Regulation of actin cytoskeleton | hsa04810 | 4.9 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
PI3K-Akt signaling pathway | hsa04151 | 4.21 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Melanoma | hsa05218 | 6.56 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Bladder cancer | hsa05219 | 7.38 | 4 | FGFR3, HRAS, KRAS, NRAS |
Natural killer cell mediated cytotoxicity | hsa04650 | 5.53 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Renal cell carcinoma | hsa05211 | 6.6 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Glioma | hsa05214 | 6.66 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Prostate cancer | hsa05215 | 6.11 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Neurotrophin signaling pathway | hsa04722 | 5.78 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Cholinergic synapse | hsa04725 | 5.88 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Choline metabolism in cancer | hsa05231 | 6.09 | 4 | HRAS, KRAS, NRAS, PIK3CA |
FoxO signaling pathway | hsa04068 | 5.63 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Chemokine signaling pathway | hsa04062 | 5.19 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Oxytocin signaling pathway | hsa04921 | 5.4 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Endometrial cancer | hsa05213 | 6.81 | 4 | HRAS, KRAS, NRAS, PIK3CA |
HTLV-I infection | hsa05166 | 4.59 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Hepatitis C | hsa05160 | 5.68 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Hepatitis B | hsa05161 | 5.52 | 4 | HRAS, KRAS, NRAS, PIK3CA |
VEGF signaling pathway | hsa04370 | 6.77 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Proteoglycans in cancer | hsa05205 | 5.02 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Estrogen signaling pathway | hsa04915 | 6.11 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Viral carcinogenesis | hsa05203 | 5.08 | 4 | HRAS, KRAS, NRAS, PIK3CA |
T cell receptor signaling pathway | hsa04660 | 6.01 | 4 | HRAS, KRAS, NRAS, PIK3CA |
B cell receptor signaling pathway | hsa04662 | 6.52 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Non-small cell lung cancer | hsa05223 | 6.88 | 4 | HRAS, KRAS, NRAS, PIK3CA |
ErbB signaling pathway | hsa04012 | 6.15 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Acute myeloid leukemia | hsa05221 | 6.74 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Chronic myeloid leukemia | hsa05220 | 6.48 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Thyroid hormone signaling pathway | hsa04919 | 5.82 | 4 | HRAS, KRAS, NRAS, PIK3CA |
MAPK signaling pathway | hsa04010 | 4.63 | 4 | FGFR3, HRAS, KRAS, NRAS |
Insulin signaling pathway | hsa04910 | 5.55 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Fc epsilon RI signaling pathway | hsa04664 | 6.6 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Prolactin signaling pathway | hsa04917 | 6.6 | 4 | HRAS, KRAS, NRAS, PIK3CA |
GnRH signaling pathway | hsa04912 | 6.18 | 3 | HRAS, KRAS, NRAS |
Gap junction | hsa04540 | 6.24 | 3 | HRAS, KRAS, NRAS |
Thyroid cancer | hsa05216 | 7.48 | 3 | HRAS, KRAS, NRAS |
Tight junction | hsa04530 | 5.53 | 3 | HRAS, KRAS, NRAS |
Long-term potentiation | hsa04720 | 6.64 | 3 | HRAS, KRAS, NRAS |
Melanogenesis | hsa04916 | 5.97 | 3 | HRAS, KRAS, NRAS |
Alcoholism | hsa05034 | 5.59 | 3 | HRAS, KRAS, NRAS |
Serotonergic synapse | hsa04726 | 5.84 | 3 | HRAS, KRAS, NRAS |
Axon guidance | hsa04360 | 5.63 | 3 | HRAS, KRAS, NRAS |
Long-term depression | hsa04730 | 6.74 | 3 | HRAS, KRAS, NRAS |
Aldosterone-regulated sodium reabsorption | hsa04960 | 7.41 | 2 | KRAS, PIK3CA |
Progesterone-mediated oocyte maturation | hsa04914 | 6.18 | 2 | KRAS, PIK3CA |
Pancreatic cancer | hsa05212 | 6.56 | 2 | KRAS, PIK3CA |
Colorectal cancer | hsa05210 | 6.52 | 2 | KRAS, PIK3CA |
Endocytosis | hsa04144 | 4.92 | 2 | FGFR3, HRAS |
Focal adhesion | hsa04510 | 4.92 | 2 | HRAS, PIK3CA |
REACTOME term | REACTOME term ID | IC | Number of genes with the same term | Genes |
---|---|---|---|---|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by FGFR3 in disease | R-HSA-5655332 | 8.52 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by Interleukins | R-HSA-449147 | 4.71 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Immune System | R-HSA-168256 | 2.37 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.62 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
IGF1R signaling cascade | R-HSA-2428924 | 4.85 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Downstream signal transduction | R-HSA-186763 | 4.65 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by ERBB4 | R-HSA-1236394 | 4.7 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by Insulin receptor | R-HSA-74752 | 4.73 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Adaptive Immune System | R-HSA-1280218 | 3.19 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Disease | R-HSA-1643685 | 3.33 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Insulin receptor signalling cascade | R-HSA-74751 | 4.85 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signalling by NGF | R-HSA-166520 | 4.23 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by VEGF | R-HSA-194138 | 4.66 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.26 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
IRS-mediated signalling | R-HSA-112399 | 4.87 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.59 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by FGFR4 | R-HSA-5654743 | 4.69 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by FGFR in disease | R-HSA-1226099 | 7.49 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by FGFR3 | R-HSA-5654741 | 4.69 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by FGFR | R-HSA-190236 | 4.67 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Diseases of signal transduction | R-HSA-5663202 | 4.89 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Interleukin-2 signaling | R-HSA-451927 | 5.05 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Innate Immune System | R-HSA-168249 | 3.17 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by SCF-KIT | R-HSA-1433557 | 4.73 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by PDGF | R-HSA-186797 | 4.53 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
DAP12 signaling | R-HSA-2424491 | 4.64 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by EGFR | R-HSA-177929 | 4.59 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by GPCR | R-HSA-372790 | 2.68 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by FGFR2 | R-HSA-5654738 | 4.68 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by FGFR1 | R-HSA-5654736 | 4.69 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
DAP12 interactions | R-HSA-2172127 | 4.56 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signaling by ERBB2 | R-HSA-1227986 | 4.66 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Signal Transduction | R-HSA-162582 | 1.78 | 5 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.15 | 4 | FGFR3, HRAS, KRAS, NRAS |
Frs2-mediated activation | R-HSA-170968 | 5.12 | 4 | FGFR3, HRAS, KRAS, NRAS |
Cell surface interactions at the vascular wall | R-HSA-202733 | 6.32 | 4 | HRAS, KRAS, NRAS, PIK3CA |
MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.11 | 4 | FGFR3, HRAS, KRAS, NRAS |
Developmental Biology | R-HSA-1266738 | 3.48 | 4 | FGFR3, HRAS, KRAS, NRAS |
RAF/MAP kinase cascade | R-HSA-5673001 | 5.15 | 4 | FGFR3, HRAS, KRAS, NRAS |
MAPK family signaling cascades | R-HSA-5683057 | 4.89 | 4 | FGFR3, HRAS, KRAS, NRAS |
Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.12 | 4 | FGFR3, HRAS, KRAS, NRAS |
FCERI mediated MAPK activation | R-HSA-2871796 | 4.32 | 4 | FGFR3, HRAS, KRAS, NRAS |
Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 8.73 | 4 | HRAS, KRAS, NRAS, PIK3CA |
FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.14 | 4 | FGFR3, HRAS, KRAS, NRAS |
SOS-mediated signalling | R-HSA-112412 | 5.15 | 4 | FGFR3, HRAS, KRAS, NRAS |
FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.14 | 4 | FGFR3, HRAS, KRAS, NRAS |
Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 9.08 | 4 | HRAS, KRAS, NRAS, PIK3CA |
SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 8.81 | 4 | FGFR3, HRAS, KRAS, NRAS |
Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 9.08 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Signaling by EGFR in Cancer | R-HSA-1643713 | 8.73 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Signaling by Leptin | R-HSA-2586552 | 5.1 | 4 | FGFR3, HRAS, KRAS, NRAS |
Signaling by FGFR1 in disease | R-HSA-5655302 | 7.81 | 4 | HRAS, KRAS, NRAS, PIK3CA |
NCAM signaling for neurite out-growth | R-HSA-375165 | 4.9 | 4 | FGFR3, HRAS, KRAS, NRAS |
Signalling to RAS | R-HSA-167044 | 5.08 | 4 | FGFR3, HRAS, KRAS, NRAS |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 8.73 | 4 | HRAS, KRAS, NRAS, PIK3CA |
SHC1 events in EGFR signaling | R-HSA-180336 | 5.15 | 4 | FGFR3, HRAS, KRAS, NRAS |
FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.14 | 4 | FGFR3, HRAS, KRAS, NRAS |
Prolonged ERK activation events | R-HSA-169893 | 5.11 | 4 | FGFR3, HRAS, KRAS, NRAS |
Signalling to ERKs | R-HSA-187687 | 5.04 | 4 | FGFR3, HRAS, KRAS, NRAS |
GRB2 events in EGFR signaling | R-HSA-179812 | 5.15 | 4 | FGFR3, HRAS, KRAS, NRAS |
SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.15 | 4 | FGFR3, HRAS, KRAS, NRAS |
ARMS-mediated activation | R-HSA-170984 | 5.12 | 4 | FGFR3, HRAS, KRAS, NRAS |
Signaling by FGFR4 in disease | R-HSA-5655291 | 9.52 | 4 | HRAS, KRAS, NRAS, PIK3CA |
FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.14 | 4 | FGFR3, HRAS, KRAS, NRAS |
Tie2 Signaling | R-HSA-210993 | 8.81 | 4 | HRAS, KRAS, NRAS, PIK3CA |
SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.15 | 4 | FGFR3, HRAS, KRAS, NRAS |
Axon guidance | R-HSA-422475 | 3.93 | 4 | FGFR3, HRAS, KRAS, NRAS |
VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.07 | 4 | FGFR3, HRAS, KRAS, NRAS |
Signaling by FGFR2 in disease | R-HSA-5655253 | 8.23 | 4 | HRAS, KRAS, NRAS, PIK3CA |
Hemostasis | R-HSA-109582 | 3.98 | 4 | HRAS, KRAS, NRAS, PIK3CA |
C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.06 | 3 | HRAS, KRAS, NRAS |
Negative regulation of MAPK pathway | R-HSA-5675221 | 7.66 | 3 | HRAS, KRAS, NRAS |
p38MAPK events | R-HSA-171007 | 9.28 | 3 | HRAS, KRAS, NRAS |
Regulation of RAS by GAPs | R-HSA-5658442 | 6.92 | 3 | HRAS, KRAS, NRAS |
SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 8.59 | 3 | HRAS, KRAS, NRAS |
MAP2K and MAPK activation | R-HSA-5674135 | 7.66 | 3 | HRAS, KRAS, NRAS |
CD209 (DC-SIGN) signaling | R-HSA-5621575 | 8.59 | 3 | HRAS, KRAS, NRAS |
EGFR Transactivation by Gastrin | R-HSA-2179392 | 9.81 | 3 | HRAS, KRAS, NRAS |
SHC-related events triggered by IGF1R | R-HSA-2428933 | 9.81 | 3 | HRAS, KRAS, NRAS |
SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 8.28 | 3 | HRAS, KRAS, NRAS |
SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 8.46 | 3 | HRAS, KRAS, NRAS |
Activation of RAS in B cells | R-HSA-1169092 | 10.66 | 3 | HRAS, KRAS, NRAS |
RAF activation | R-HSA-5673000 | 8.34 | 3 | HRAS, KRAS, NRAS |
PI3K/AKT activation | R-HSA-198203 | 6.32 | 2 | FGFR3, PIK3CA |
PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 6.56 | 2 | FGFR3, PIK3CA |
PI3K Cascade | R-HSA-109704 | 6.68 | 2 | FGFR3, PIK3CA |
PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.37 | 2 | FGFR3, PIK3CA |
PI-3K cascade:FGFR1 | R-HSA-5654689 | 6.37 | 2 | FGFR3, PIK3CA |
PI3K events in ERBB4 signaling | R-HSA-1250342 | 6.37 | 2 | FGFR3, PIK3CA |
Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 7.05 | 2 | FGFR3, PIK3CA |
PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.37 | 2 | FGFR3, PIK3CA |
PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.37 | 2 | FGFR3, PIK3CA |
GAB1 signalosome | R-HSA-180292 | 6.31 | 2 | FGFR3, PIK3CA |
PIP3 activates AKT signaling | R-HSA-1257604 | 6.37 | 2 | FGFR3, PIK3CA |
PI-3K cascade:FGFR2 | R-HSA-5654695 | 6.37 | 2 | FGFR3, PIK3CA |
Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 4.95 | 2 | FGFR3, PIK3CA |
Term | New enriched term | IC | P value | Genes |
---|---|---|---|---|
endosomal part (GO:0044440) | NEW | 3.73 | 0.011 | HRAS, KRAS, NRAS, PIK3CA |
extracellular matrix (GO:0031012) | NEW | 3.81 | 0.004 | FGFR3, HRAS, KRAS, PIK3CA |
cytosolic part (GO:0044445) | NEW | 4.34 | 0.009 | HRAS, KRAS, PIK3CA |
integral component of plasma membrane (GO:0005887) | NEW | 2.57 | 0.023 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
plasma membrane (GO:0005886) | - | 1.39 | 0.021 | FGFR3, HRAS, KRAS, NRAS, PIK3CA |
Golgi membrane (GO:0000139) | - | 3.28 | 0.032 | HRAS, KRAS, NRAS, PIK3CA |
endosome membrane (GO:0010008) | NEW | 3.83 | 0.009 | HRAS, KRAS, NRAS, PIK3CA |